These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 16996172)
1. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Al Tarique A; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA; Vaccine; 2007 Jan; 25(2):231-8. PubMed ID: 16996172 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia. Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522 [TBL] [Abstract][Full Text] [Related]
3. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Chowdhury MI; Sheikh A; Qadri F Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255 [TBL] [Abstract][Full Text] [Related]
5. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608 [TBL] [Abstract][Full Text] [Related]
6. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. Qadri F; Chowdhury MI; Faruque SM; Salam MA; Ahmed T; Begum YA; Saha A; Alam MS; Zaman K; Seidlein LV; Park E; Killeen KP; Mekalanos JJ; Clemens JD; Sack DA; J Infect Dis; 2005 Aug; 192(4):573-9. PubMed ID: 16028125 [TBL] [Abstract][Full Text] [Related]
7. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Qadri F; Ahmed T; Ahmed F; Begum YA; Sack DA; Svennerholm AM; Vaccine; 2006 Mar; 24(10):1726-33. PubMed ID: 16257098 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults. Valera R; García HM; Jidy MD; Mirabal M; Armesto MI; Fando R; García L; Fernández R; Año G; Cedré B; Ramírez M; Bravo L; Serrano T; Palma S; González D; Miralles F; Medina V; Nuñez F; Plasencia Y; Martínez JC; Mandarioti A; Lugones J; Rodríguez BL; Moreno A; González D; Baro M; Solis RL; Sierra G; Barbera R; Domínguez F; Gutiérrez C; Kouri G; Campa C; Menéndez J Vaccine; 2009 Nov; 27(47):6564-9. PubMed ID: 19720365 [TBL] [Abstract][Full Text] [Related]
9. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults]. Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092 [TBL] [Abstract][Full Text] [Related]
10. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967 [TBL] [Abstract][Full Text] [Related]
11. Peru-15 (Choleragarde(®)), a live attenuated oral cholera vaccine, is safe and immunogenic in human immunodeficiency virus (HIV)-seropositive adults in Thailand. Ratanasuwan W; Kim YH; Sah BK; Suwanagool S; Kim DR; Anekthananon A; Lopez AL; Techasathit W; Grahek SL; Clemens JD; Wierzba TF Vaccine; 2015 Sep; 33(38):4820-6. PubMed ID: 26241948 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Launay O; Sadorge C; Jolly N; Poirier B; Béchet S; van der Vliet D; Seffer V; Fenner N; Dowling K; Giemza R; Johnson J; Ndiaye A; Vray M; Sansonetti P; Morand P; Poyart C; Lewis D; Gougeon ML Vaccine; 2009 Feb; 27(8):1184-91. PubMed ID: 19135496 [TBL] [Abstract][Full Text] [Related]
13. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807 [TBL] [Abstract][Full Text] [Related]
15. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding. Ahmed T; Svennerholm AM; Al Tarique A; Sultana GN; Qadri F Vaccine; 2009 Feb; 27(9):1433-9. PubMed ID: 19146904 [TBL] [Abstract][Full Text] [Related]
16. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vesikari T; Karvonen A; Korhonen T; Espo M; Lebacq E; Forster J; Zepp F; Delem A; De Vos B Vaccine; 2004 Jul; 22(21-22):2836-42. PubMed ID: 15246619 [TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Cohen MB; Giannella RA; Bean J; Taylor DN; Parker S; Hoeper A; Wowk S; Hawkins J; Kochi SK; Schiff G; Killeen KP Infect Immun; 2002 Apr; 70(4):1965-70. PubMed ID: 11895960 [TBL] [Abstract][Full Text] [Related]
19. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children. Saha A; Chowdhury MI; Nazim M; Alam MM; Ahmed T; Hossain MB; Hore SK; Sultana GN; Svennerholm AM; Qadri F Vaccine; 2013 Jan; 31(4):647-52. PubMed ID: 23200936 [TBL] [Abstract][Full Text] [Related]
20. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate. Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]